A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-426
- Sponsors Merck Sharp & Dohme Corp.
- 04 Jun 2024 Results of biomarker analysis assessing TcellinfGEP with clinical outcomes presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 04 Mar 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2025.
- 01 Nov 2023 Results of final protocol-prespecified analysis, published in the European Urology